Torrent Pharma Q2 profit falls 9.6% to ₹534 crore, revenue rises 51%
Torrent Pharmaceuticals moved lower in a quarterly results development for Q2FY27.
· BS Companies
Torrent Pharma's Q2FY27 net profit declined 9.6 per cent to ₹534 crore despite a 50.8 per cent rise in revenue, as higher finance costs and depreciation weighed on…
Key facts
- Period
- Q2FY27
The analysis
Torrent Pharmaceuticals reported ₹534 crore for Q2FY27, with movement of 51%, 9.6% and 50.8% attached to those lines. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.
Against that, the stock is -2.0% on the day at ₹4,524.40, and has returned -8.3% over three months. It sits 12% below its 52-week high. The pharma & healthcare sector has moved -4.9% over the same period, so Torrent Pharmaceuticals is running 3.4 points behind its peers.
For Torrent Pharmaceuticals, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.
Why it matters
- Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Market context
- The company directly in focus is TORNTPHARM.
- Sector exposure: Pharma & Healthcare.
- The immediate tone of coverage reads negative.
In this story
Related coverage
Adani Green Q2 Results: Profit rises 15% YoY to Rs 673 crore; revenue jumps 39%
Lupin, SRF, TMPV, Maruti, NTPC among 74 BSE 500 stocks hit 52-week lows
Tata Motors CV Q2 Results Preview: Profit may rise up to 44% YoY, revenue 45%; margins, volume growth in focus
Havells Q2 net profit rises 9.7% to ₹349 cr as revenue grows 34.6%
ICICI Prudential Life Insurance to focus on growing absolute VNB amid slump in FY24